Vimizim elosulfase alfa regulatory update

BioMarin said EMA's CHMP issued a positive opinion recommending approval of the company's Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome), a rare inherited lys...